Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activity
Koji Shinoda(Kyushu University), Amit Bar‐Or(University of Pennsylvania)
Cited by 58
Related Papers
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
|New England Journal of Medicine|2016|2k
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
|New England Journal of Medicine|2016|1.9k
Multiple sclerosis
|Nature Reviews Disease Primers|2018|1.4k
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
|The Lancet|2011|743
Ofatumumab versus Teriflunomide in Multiple Sclerosis
|New England Journal of Medicine|2020|706